QMBlog Content
Discover More:
// November 27, 2023
Building a More Resilient Medicines Supply Chain
Building a More Resilient Medicines Supply Chain
In this Q&A with the Duke-Margolis Drug Supply Chain Resilience and Advanced Manufacturing Consortium, US Pharmacopeia (USP) policy expert Amy B. Cadwallader highlights the importance of multi-disciplinary, cross-functional coordination to strengthen the medicine supply chain and global public health resilience in the face of ongoing threats, like persistent drug shortages. This Q&A was first published in the Consortium's eNewsletter and is re-printed with the permission of the Duke-Margolis Center for Health Policy.
// November 27, 2023
Revisiting the Landscape of Potential Nitrosamines in Pharmaceuticals using CPCA fram...
USP’s Naiffer Romero has teamed up with researchers at LHASA Limited, AstraZeneca, Sai Life Sciences and Merck for collaborative research on nitrosamines impurities that was published this month in the Journal of Pharmaceutical Sciences. Quality Matters recently sat down with Romero, who leads USP’s Nitrosamines Exchange, to learn more about the new research and what it means for the field.
// October 24, 2023
Mitigating Cancer Drug Shortages: USP-American Cancer Society Summit Issues Call to A...
Patient access to cancer drugs can mean the difference between life and death. Persistent shortages threaten patients’ access to the lifesaving and life-sustaining therapies they need.
// September 21, 2023
Ensuring Product Safety: U.S. FDA Guidance on Testing High-Risk Drug Components for D...
Excipients, or inactive ingredients, in a drug formulation are critical components, comprising up to 90% of a drug formulation by volume and serving important functions such as improving stability and increasing bioavailability for targeted drug delivery. However, with so much focus on the quality of active ingredients in the complex pharmaceutical supply chain, the quality of inactive ingredients is, at times, overlooked.